iBio, Inc. subsidiary iBio CDMO entered into a purchase and sale agreement to sell its biologics manufacturing facility for $17.25 million; iBio CDMO also entered into a sixth amendment to its credit agreement to set the maturity date of the term loan and apply the net proceeds from the sale to pay off the loan.